DrugPatentWatch Database Preview
Details for Patent: 8,497,277
» See Plans and Pricing
Which drugs does patent 8,497,277 protect, and when does it expire?
Patent 8,497,277 protects IMBRUVICA and is included in two NDAs.
This patent has one hundred and fifty-nine patent family members in twenty-six countries.
Summary for Patent: 8,497,277
| Title: | Inhibitors of Bruton's tyrosine kinase |
| Abstract: | Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
| Inventor(s): | Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX) |
| Assignee: | Pharmacyclics, Inc. (Sunnyvale, CA) |
| Application Number: | 13/312,606 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,497,277 |
|
Patent Claim Types: see list of patent claims | Use; Device; Delivery; |
Drugs Protected by US Patent 8,497,277
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-003 | Feb 16, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,497,277
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 531263 | Start Trial | |||
| Australia | 2006348662 | Start Trial | |||
| Australia | 2008232762 | Start Trial | |||
| Australia | 2010201052 | Start Trial | |||
| Australia | 2012205166 | Start Trial | |||
| Brazil | PI0622054 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
